About
Antibody Therapies for Oncology
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyNJ, NY, PA
Clinical Trials (29)
View allTotal Trials
29
As Lead Sponsor
15
As Collaborator
14
Total Enrollment
1,675
By Phase
PHASE1/PHASE2: 7PHASE1: 10PHASE2: 8PHASE2/PHASE3: 1EARLY_PHASE1: 1NA: 1
By Status
TERMINATED: 8ACTIVE_NOT_RECRUITING: 7RECRUITING: 6COMPLETED: 4WITHDRAWN: 3NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline28 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
Today
Hover over trial bars to see details
Recent Trials
NCT07011654Collaborator
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
PHASE1/PHASE2Recruiting
31 participants
Started: Sep 19, 2025 · Completed: Jul 1, 2030
NCT07027748Collaborator
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
PHASE1Recruiting
18 participants
Started: Jun 27, 2025 · Completed: Dec 1, 2027
NCT05994157Lead Sponsor
Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma
PHASE1Recruiting
30 participants
Started: Feb 28, 2025 · Completed: Jan 31, 2028
NCT05130255Lead Sponsor
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
PHASE1Recruiting
60 participants
Started: Nov 17, 2022 · Completed: Apr 30, 2027
NCT05489887Collaborator
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
PHASE2Recruiting
93 participants
Started: Sep 14, 2022 · Completed: Sep 30, 2036
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...